Ena Prossner

Dr Ena Prosser is a Partner in Fountain Healthcare Partners since the initial fund raising in 2008 and the two subsequent funds.
Ena is a PhD biotechnologist by training and has a broad background in investment, international alliance and intellectual property management.
She has led due diligence projects on technologies and products within the specialty pharma, diagnostic, device and biotechnology areas.
At Fountain, Ena has led several investment including Genable (Ire) Ltd (sold to Spark Therapeutics Inc in 2013), led the Series B investment in NeRRe Therapeutics(UK) Ltd and KaNDy Therapeutics (UK) Ltd (acquired by Bayer, 2020), joined the board of Inotrem S.A. in Paris in 2020 and Netherlands-based Calypso Biotech in 2021.
Ena was formerly Director of BioResearch Ireland at Enterprise Ireland.
In this role, she led a large team to identify, fund, protect and exploit relevant Intellectual Property, commercialise lifescience technologies and review investment opportunities in R&D.
Prior to Enterprise Ireland, Ena held various R&D and project management roles within Elan Corporation and had extensive involvement in drug delivery development, licensing and acquisition projects over a 9-year period.
Ena has a strong innovation policy background and was a member of the Irish Government Innovation Taskforce in Intellectual Property, ICSTI and Knowledge Transfer Ireland.
Ena works closely with leading ophthalmology research charity Fighting Blindness Ireland and the INFANT Research Center based in UCC (Ireland).
Ena is an Adjunct Professor at University College Dublin and a member of the Institute of Directors (Ireland).